Prot #M16-046: A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis

Project: Research project

Project Details

StatusFinished
Effective start/end date8/28/19 → 8/28/20

Funding

  • AbbVie Inc. (Prot #M16-046)